Piper Sandler: 'Time Is Right to Own Structure Therapeutics (GPCR) Now'

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $93.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented: "Time Is Right to Own GPCR Now & Here Is Why in Our Deep Dive; GPCR sold off in the beginning of the year due to a lack of near-term catalysts where we believe LLY's (not covered) orforglipron Ph3 ATTAIN-1 topline (August 2025) stimulated a trade-up into aleniglipron's 36-week Ph2b ACCESS/ACCESS II data 4Q25 (~early/ mid-December, per our math). Specifically, we have high PoS 120 mg aleniglipron will achieve the bar of placebo-adjusted ΔΔ 10% weight loss at week 36 with clean safety/ tolerability given its 12-week Ph2a efficacy and optimized titration scheme. We also believe strategic interest remains high given the current environment and recent transactions in the metabolic space. GPCR continues to develop their amylin program with ACCG-2671 Ph1 SAD/MAD initiation and second amylin DC selection YE25. Thus, we believe it is an opportune time to own GPCR ahead of Ph2b ACCESS/ACCESS II readouts which should validate aleniglipron's differentiated product profile and position it as Ph3-ready."

For an analyst ratings summary and ratings history on Structure Therapeutics click here. For more ratings news on Structure Therapeutics click here.

Shares of Structure Therapeutics closed at $28.65 yesterday.

You May Also Be Interested In

• Equirus Starts JSW Energy Ltd (JSW:IN) at Long (1)
• Holtec Nuclear Corporation files for initial public offering
• Healthcare Triangle, Inc (HCTI) files for 28M share offering by selling stockholders